Researchers found that pembrolizumab, an immune-activating cancer drug, lowered the risk of distant metastases in patients with Merkel cell carcinoma after surgery. Though recurrence rates overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback